273 related articles for article (PubMed ID: 35443042)
1. Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.
Martini DJ; Chen YB; DeFilipp Z
Oncologist; 2022 Aug; 27(8):685-693. PubMed ID: 35443042
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
[TBL] [Abstract][Full Text] [Related]
3. Three US Food and Drug Administration-approved therapies for chronic GVHD.
Zeiser R; Lee SJ
Blood; 2022 Mar; 139(11):1642-1645. PubMed ID: 35081254
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
Zhang MY; Zhao P; Zhang Y; Wang JS
PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
[TBL] [Abstract][Full Text] [Related]
5. Role of Ruxolitinib in Steroid-Refractory Graft versus Host Disease in Patients Undergoing Allogeneic Stem Cell Transplant.
Javed H; Chaudhry Q; Shahbaz N; Khan MA; Iftikhar R; Yousaf M
J Coll Physicians Surg Pak; 2022 Sep; 32(9):1225-1227. PubMed ID: 36089728
[TBL] [Abstract][Full Text] [Related]
6. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.
Jaglowski SM; Blazar BR
Blood Adv; 2018 Aug; 2(15):2012-2019. PubMed ID: 30108109
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib for the treatment of graft-versus-host disease.
Ali H; Salhotra A; Modi B; Nakamura R
Expert Rev Clin Immunol; 2020 Apr; 16(4):347-359. PubMed ID: 32153201
[No Abstract] [Full Text] [Related]
8. Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program.
Schroeder MA; Hari PN; Blithe A; Paranagama D; Bhatt V; DiPersio JF
Bone Marrow Transplant; 2022 Jun; 57(6):975-981. PubMed ID: 35437311
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
[TBL] [Abstract][Full Text] [Related]
10. Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients.
Gagliardi TA; Milner J; Cairo MS; Steinberg A
Cureus; 2022 Sep; 14(9):e29195. PubMed ID: 36258935
[TBL] [Abstract][Full Text] [Related]
11. Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease.
Kasikis S; Etra A; Levine JE
BioDrugs; 2021 Jan; 35(1):19-33. PubMed ID: 33201499
[TBL] [Abstract][Full Text] [Related]
12. Belumosudil for chronic graft-versus-host disease.
Taylor B; Cohen J; Tejeda J; Wang TP
Drugs Today (Barc); 2022 May; 58(5):203-212. PubMed ID: 35535812
[TBL] [Abstract][Full Text] [Related]
13. Acute graft-versus-host disease.
Malard F; Holler E; Sandmaier BM; Huang H; Mohty M
Nat Rev Dis Primers; 2023 Jun; 9(1):27. PubMed ID: 37291149
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
[TBL] [Abstract][Full Text] [Related]
15. Novel therapies for graft versus host disease with a focus on cell therapies.
Zeiser R; Ringden O; Sadeghi B; Gonen-Yaacovi G; Segurado OG
Front Immunol; 2023; 14():1241068. PubMed ID: 37868964
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
[TBL] [Abstract][Full Text] [Related]
17. [Evolving treatment strategies for chronic graft-versus-host disease].
Inamoto Y
Rinsho Ketsueki; 2022; 63(5):433-439. PubMed ID: 35662168
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.
Uygun V; Karasu G; Daloğlu H; Öztürkmen S; Kılıç SÇ; Yalçın K; Çelen SS; Hazar V; Yeşilipek A
Pediatr Blood Cancer; 2020 Apr; 67(4):e28190. PubMed ID: 31981413
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience.
Spałek A; Wieczorkiewicz-Kabut A; Koclęga A; Woźniczka K; Węglarz P; Boral K; Kata D; Zielińska P; Helbig G
Int J Hematol; 2022 Dec; 116(6):922-928. PubMed ID: 35972605
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
Abedin SM; Hamadani M
Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
